ATLANTA Sciele Pharma and Novo Nordisk have signed an exclusive agreement to market Prandin and, when approved, PrandiMet. Prandin is an oral blood glucose-lowering drug used in the management of Type 2 diabetes. PrandiMet is a combination of Prandin and metformin.
Under the agreement, Sciele will exclusively market Prandin and PrandiMet to physicians in the U.S. and will have the first right to market any new products containing the active pharmaceutical ingredient in Prandin.
“We are pleased to initiate this partnership with Novo Nordisk, a company that is widely recognized as a global leader in diabetes care,” Patrick Fourteau, president and chief executive officer of Sciele Pharma, added. “Prandin and, potentially, PrandiMet [upon approval by the Food and Drug Administration] fit well within our diabetes product portfolio and will be an excellent complement to Fortamet. Promoted by our Primary Care sales force, Prandin and PrandiMet will strengthen our presence in the diabetes treatment market.”